The Difference Between Using Local and General Dexamethasone in Arthroscopic Anterior Cruciate Ligament Repair

Not Applicable

Completed

• Conditions: ACL Injury
• Interventions: Drug: Dexamethasone injection; Drug: Bupivacaine 0.375% Injectable Solution; Drug: Bupivacaine 0.5% Injectable Solution

• Registration Number: NCT06537518
• Lead Sponsor: Benha University

Brief Summary

Arthroscopic knee injuries, such as the anterior cruciate ligament (ACL) injury, are common and often result in postoperative pain. Regional anesthetic techniques, such as femoral nerve block (FNB) and adductor canal block (ACB), can help alleviate pain and reduce opioid consumption. ACB, which blocks the saphenous nerve and obturator nerve branches, is preferred over FNB due to its potential to decrease mobility and increase falls risk. Dexamethasone, a potent glucocorticoid, is used as an adjuvant for ACB, but its perineural administration may carry neurotoxicity risks. Some pain physicians prefer intravenous administration to prolong the action of local anesthetics used in peripheral nerve blocks.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-05-01
• Primary Completion: 2022-11-20
• Study Completion: 2022-12-25
• Study First Submitted: 2024-07-26
• Status Verified: 2024-08
• Study First Submitted QC: 2024-08-01
• Last Update Submitted: 2024-08-01
• Study First Posted: 2024-08-05
• Last Update Posted: 2024-08-05

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 123

Inclusion Criteria

• Patients diagnosed with ACL injury;
• Patients in class I, II according to American Society of Anesthesiologists (ASA) classification.

Exclusion Criteria

• Patients free of all Inclusion Criteria.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
IV anesthetic Group	Dexamethasone injection	-
Local anesthetic Group	Dexamethasone injection	-
Local anesthetic Group	Bupivacaine 0.5% Injectable Solution	-
Control Group	Bupivacaine 0.375% Injectable Solution	-
IV anesthetic Group	Bupivacaine 0.375% Injectable Solution	-

Primary Outcome Measures

Name	Time	Method
Proportion of patients reporting at least a 50% reduction in pain (measured by Numerical Rating Scale) post-arthroscopic ACL management.	6 months	Value of administration of dexamethasone enhancing the analgesic action of bupivacaine used in ACB after arthroscopic management of the ACL.

Trial Locations

Locations (1)

Benha faculty of Medicine; 🇪🇬 Banhā, El Qalyoubia, Egypt